(click to change)
(click to change) Diagnosis required Hgb: g/L Date: Ferritin: ug/L Date: Date: Date:
Stamp Signature
IV IRON (Venofer) Iron sucrose 300 mg IV in sodium chloride 0.9% 250 mL. Give every 1 to 4 days for a total of 3 doses (to be completed within 14 days). Administer over at least 90 minutes.
Prescriber College ID Prescriber Phone
INFUSION REACTIONS: If signs of hypersensitivy or anaphylaxis, STOP infusion immediately and notify physician. Follow guideline for Anaphylaxis: Clinical Practice Guideline (Registered Nurse Initiated Activity - 2009). Infusion reaction medications:
Acetaminophen 650 mg PO x 1
Epinephrine 1 mg/mL (1:1000) 0.5 mL IM for anaphylaxis
DiphenhydraAMINE 25 to 50 mg IV x 1 for urticaria / pruritus
Prescriber College ID Prescriber Phone
CGH Pre-Printed Order for Adult Parenteral IRON SUCROSE INFUSION Any required out-patient laboratory tets are to be arranged from physician’s office.
  • Indications for parenteral iron therapy:
  • Relevant Patient History:
  • Physician’s office to send all relevant blood work to outpatient department.
       NOTE: Guildelines fo rcalculating iron requirements on back of page.
  • Intermittent Iron Sucrose IV dose:
  • Frequency and Duration:
  • LBW/Dose Calculator Body Weight (kg): Lean Body Weight (kg): Current Hgb (g/L): Desired Hgb (g/L): Dose required (mL): Elemental Fe required (mg):
    Management of Side Effects: If Adverse Reaction see PDTM:
  • Hold infusion x 30 minutes
  • If symptoms improve resume infusion at half previous rate
  • If symptoms persist give 500 mL 0.9% NaCL bolus and call physician
  • If Anaphylactic reaction occurs:
  • Stop infusion immediately and call physician
  • Initiate O2 by mask
  • DiphenhydraAMINE 25 to 50 mg IV x 1 dose
  • EPIneprhine 1:1000) 0.5 mL IM STAT
  • Prescriber College ID Prescriber Phone
    Subject:
    Creative Commons License FHA Medical Day Care Clinic eFORM, V4_Jun22_2022, by Dr. John Yap, is licensed under a GPL.
    Please consider supporting oscarbc.ca | info@oscarbc.ca | Facebook | Twitter | LinkedIn |